Introduction
Effective endovascular therapy for femoropopliteal segment is spreading around the world, though high-risk cases and lesions for vessel patency after procedure remain. 1 To solve this problem, new approaches are being developed using advanced drug technologies, including a promising 'nothing left behind' strategy. 2, 3 Drug-coated balloon (DCB) angioplasty is a hopeful treatment; however, long-term drug effects are uncertain because DCB has not been extensively used in peripheral intervention yet. We are presently following a case where healing of dissection is apparent 3 months after DCB angioplasty was performed in the femoropopliteal segment.
Case report
An early 80s male presented for left leg intermittent claudication caused by atherosclerotic stenosis at left external iliac artery (EIA) and middle of superficial femoral artery (SFA). He also had chronic atrial fibrillation, diabetes mellitus, and hypertension. His informed consent allowed us to perform endovascular therapy. According to intravascular ultrasonography (IVUS) images, 8.0-40 mm S.M.A.R.T. control stent (Cordis, USA) was deployed for EIA lesion by contra-lateral approach and short (2 cm lesion length) SFA lesion was decided with DCB angioplasty. After preparation using 4.0-40 mm NSE balloon (Nipro, Japan), angioplasty using DCB (5.0-40 mm IN.PACT Admiral; Medtronic, USA) was done at nominal pressure for 5 min and resulted in 50% residual stenosis with linear dissection. Provisional stenting was not done because decent ante-grade blood flow allowed 10 extra Healing of femoral artery dissection after drug-coated balloon angioplasty: A case report with intravascular ultrasonography and angioscopy images minutes. Medication involved ongoing use of aspirin 100 mg and rivaroxaban 15 mg. Angiography 3 months from index procedure showed EIA and SFA patency and healing of intimal dissection at SFA lesion was estimated by IVUS ( Figure 1) . In angioscopy findings, red thrombus was seen in dissection cavity (Figure 2 ) but no white granular materials were seen at DCB dilated segment.
Discussion
We reported that balloon angioplasty in SFA segment resulted in optimal dilatation and good outcomes were achieved; 4 however, balloon angioplasty sometimes leads to major intimal dissection. Depending on the magnitude of dissection occurrence, restenosis risk would be higher. 5 Based on these experiences, provisional stenting had been selected for dissection occurrences after balloon angioplasty in past nitinol stenting era. However, healing effect of DCB for dissection has been reported in coronary intervention recently. 6, 7 In our case, linear dissection occurred after DCB angioplasty at the end of index procedure and healing change of intimal flap was in IVUS findings 3 months later. We feel this observation could be important, showing possibility of dissection healing effect of DCB even in peripheral intervention -possibly similar to coronary intervention.
It is well-known that shorter lesions could have better prognosis in endovascular therapy. 8 The clinical course of our case might simply depend on its short lesion length, but further case studies might be necessary.
From angioscopy findings, thrombus might be suspect to have some role in the healing process of dissection from our case, but to the best of our knowledge, no reports have discussed these findings.
Using direct oral anticoagulants (DOACs) after procedure therapy, a recent report 9 showed non-inferior effect on vessel patency compared with standard dual antiplatelet therapy after SFA intervention. That report might involve almost half of patients who ended up with non-stenting strategy; however, prevalence of DCB use was not described.
Further prospective randomized investigation about dissection healing effect of DCB, role of thrombus, and efficacy of combination with DOAC use in peripheral intervention should be studied.
Conclusion
In this case, possible healing effect of DCB for dissection occurred in SFA segment was estimated in angiography and IVUS findings.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
Informed consent
Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article. Taketsugu Tsuchiya https://orcid.org/0000-0001-8152-7039
ORCID iD

